Loading...
Following FDA approval of sorafenib for renal cancer in 2005, three additional tyrosine kinase inhibitors of VEGF have gained regulatory approval, and two of them — sunitinib and pazopanib — have been approved as initial therapy. These active drugs have clearly improved patient outcomes, but they are not curative, and their toxic effects, including fatigue, hypertension, hand-foot syndrome, and myelosuppression, are problematic in the long term.
To compare the efficacy and safety of pazopanib versus sunitinib as initial therapy in metastatic renal cancer, international investigators conducted a phase III, randomized trial sponsored by the maker of pazopanib, in which 1110 patients were randomized to the standard dose and schedule of either d…